Literature DB >> 27478613

Erratum: Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.

Naoka Murakami1, Thiago J Borges1, Michifumi Yamashita2, Leonardo V Riella3.   

Abstract

[This corrects the article on p. 411 in vol. 9, PMID: 27274826.].

Entities:  

Year:  2016        PMID: 27478613      PMCID: PMC4957732          DOI: 10.1093/ckj/sfw058

Source DB:  PubMed          Journal:  Clin Kidney J        ISSN: 2048-8505


In the original published version of this paper there was a small textual error on page 3, and an error in the figure caption for fig. 4 on page 4. Old version: p. 3: ‘Furthermore, serum cytokine analysis revealed a strikingly high level of pro-inflammatory cytokines (IL-1Ra, CXCL10 and TNF-α) (Figure 4F-H) and soluble IL-2 receptor (32 400 pg/mL; reference range <1033 pg/mL).’ p.4, Fig.4 caption: ‘Pro-inflammatory cytokines (IL-1Ra, CXCL10 and TNF-α) were strikingly higher in the patient (F-H_. New version: p.3: ‘Furthermore, serum cytokine analysis revealed a strikingly high level of IL-1Ra, pro-inflammatory cytokines (CXCL10 and TNF-α) (Figure4F–H) and soluble IL-2 receptor (32 400 pg/mL; reference range <1033 pg/mL).’ p.4: ‘IL-1Ra (F) and proinflammatory cytokines (CXCL10 and TNF-α) were strikingly higher in the patient (G,H).’
  3 in total

Review 1.  Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases.

Authors:  Sandra Assoun; Virginie Lemiale; Elie Azoulay
Journal:  Intensive Care Med       Date:  2019-05-29       Impact factor: 17.440

2.  Farewell from the CKJ Editor-in-Chief: key kidney topics from 2014 to 2021.

Authors:  Alberto Ortiz; Caroline Vinck
Journal:  Clin Kidney J       Date:  2022-03-31

3.  Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment.

Authors:  Sachi Okawa; Keiichi Fujiwara; Atsushi Shimonishi; Hiroaki Matsuura; Taichi Ozeki; Jun Nishimura; Hiroe Kayatani; Daisuke Minami; Yoko Shinno; Ken Sato; Kosuke Ota; Takuo Shibayama
Journal:  Case Rep Oncol       Date:  2020-02-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.